Diabetes mellitus and coronary heart disease - From prevention to intervention: Part I

Australian and New Zealand Journal of Medicine

Volumn 30, Issue 3, 2000, Pages 351-359

  Farouque, H M Omar ^a   O'Brien, R C ^a   Meredith, Ian T ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GEMFIBROZIL; LISINOPRIL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN;

ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG TOLERANCE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SMOKING;

EID: 0033939030     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2000.tb00837.x     Document Type: Review

References (69)

1. 1. Garber AJ. Vascular disease and lipids in diabetes. In: Skyler JS, ed. The Medical Clinics of North America: prevention and treatment of diabetes and its complications. Philadelphia: W B Saunders, 1998: 931-48.
2. 2. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham study. Am Heart J 1985; 110: 1100-7.
3. 3. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol 1993; 46: 245-52.
4. 4. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-85.
5. 5. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291-7.
6. 6. Granger C, Califf R, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents: The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920-5.
7. 7. Stone PH, Muller JE, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to adverse prognosis. J Am Coll Cardiol 1989; 14: 49-57.
8. 8. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomised trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997; 96: 1761-9.
9. 9. Bierman EL. George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 1992; 12: 647-56.
10. 10. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
11. 11. Cooper MA, Gilbert RE, Jerums G. Diabetic vascular complications. Clin Exp Pharmacol Physiol 1997; 24: 770-5.
12. 12. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
13. 13. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
14. 14. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager M. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-16.
15. 15. Williams SB, Cusco JA, Roddy M-A, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-74.
16. 16. Giugliano D, Marfella R, Coppola L et al. Vascular effects of acute hyperglycaemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycaemia. Circulation 1997; 95: 1783-90.
17. 17. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycaemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-701.
18. 18. Poston L. Endothelial control of vascular tone in diabetes mellitus. Diabetologia 1997; 40: S113-S114.
19. 19. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
20. 20. Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
21. 21. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-91.
22. 22. Silveira AM, Sjoberg S, Blomback M, Ostman J. von Willebrand factor antigen in plasma and urine in patients with type I (insulin-dependent) diabetes mellitus with and without nephropathy. J Diabetes Complications 1992; 6: 89-95.
23. 23. Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-50.
24. 24. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the haemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993; 19: 122-8.
25. 25. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1-7.
26. 26. The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
27. 27. The Diabetes Control and Complications Trial Research Group (DCCT). Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
28. 28. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
29. 29. Klimt C, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes mellitus. Diabetes 1970; 19: 747-830.
30. 30. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
31. 31. Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996; 334: 574-9.
32. 32. Despres J-P, Lamarche B, Mauriege P et al. Hyper-insulinaemia as an independent risk factor for ischaemic heart disease. N Engl J Med 1996; 334: 952-7.
33. 33. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821-7.
34. 34. Guidelines Subcommittee of the World Health Organisation-International Society of Hypertension (WHO-ISH). 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
35. 35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-13.
36. 36. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
37. 37. Tuomilehto L Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
38. 38. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982 285: 685-8.
39. 39. Chaturvedi N, Sjolie A-K, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
40. 40. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
41. 41. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-6.
42. 42. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
43. 43. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317: 713-20.
44. 44. Tatti P, Pahor M, Byington RB et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
45. 45. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nislodipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
46. 46. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
47. 47. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-93.
48. 48. Mathiesen E, Hommel E, Smith U, Parving H-H. Efficacy of captopril in normotensive diabetic patients with microalbuminuria - 8 years follow-up. Diabetologia 1995; 38 (Suppl. 1): A46.
49. 49. Agardh CD, Garcia Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-92.
50. 50. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
51. 51. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
52. 52. Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-60.
53. 53. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-8.
54. 54. Haffner SM. Management of dyslipidaemia in adults with diabetes. Diabetes Care 1998; 21: 160-78.
55. 55. Garg A. Management of dyslipidaemia in IDDM patients. Diabetes Care 1994; 17: 224-34.
56. 56. Sosenko JM, Breslow JL, Miettinen OS, Gabbay KH. Hyperglycaemia and plasma lipid levels: a prospective study of young insulin-dependent diabetic patients. N Engl J Med 1980; 302: 650-4.
57. 57. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12: 1496-502.
58. 58. Skyrme-Jones RA, O'Brien RC, Luo M, Meredith IT. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. J Am Coll Cardiol 2000; 35: 292-9.
59. 59. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-99.
60. 60. Sobenin IA, Tertov W, Koschinsky T et al. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 1993; 100: 41-54.
61. 61. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia 1987; 30: 916-23.
62. 62. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5.
63. 63. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). [published erratum appears in Diabetes Care 1997; 20: 1048]. Diabetes Care 1997; 20: 614-20.
64. 64. Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999; 159: 2661-7.
65. 65. Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-9.
66. 66. The Long-Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
67. 67. Keech A, Colquhoun D, Baker J et al. Benefits of long term cholesterol lowering therapy using pravastatin among patients with diabetes in the LIPID Study. Aust NZ J Med 2000; 30: 172.
68. 68. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-18.
69. 69. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.